GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Johnson & Johnson announces positive Phase II results for Tecvayli in newly diagnosed multiple myeloma, with all patients ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®▼ (teclistamab) from two investigational studies in patients with newly diagnosed ...

Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...

Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...

Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...

Genmab's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak. See why I rate ...

Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today announced the op ...

DelveInsight, a leader in healthcare competitive intelligence and consulting, released a case study on Competitive ...

Other drugs are expected to pull in higher revenues, with Carvykti set to make $5.9bn and Tecvayli $6.4bn in the same year. The Blenrep combo treatment could offer advantages compared to CAR-T therapy ...

Women who have uterine fibroids or endometriosis are more likely to get cancer They are also more likely to die prematurely, research shows The findings are a cautionary note for doctors and ...